Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Castle Biosciences, Inc. - Common stock
(NQ:
CSTL
)
18.39
-0.80 (-4.17%)
Streaming Delayed Price
Updated: 2:54 PM EDT, Apr 4, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Castle Biosciences, Inc. - Common stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
May 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
May 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer
May 20, 2022
From
Castle Biosciences
Via
Business Wire
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
May 19, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
May 11, 2022
Finding micro-cap stocks to buy requires a bit of everything, including patience. Today's plan is to pick from the top of the IWC ETF.
Via
InvestorPlace
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
May 10, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Reports First Quarter 2022 Results
May 09, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
May 06, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
May 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
April 29, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
April 27, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Completes Acquisition of AltheaDx
April 26, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
April 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
April 21, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
April 20, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
April 18, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
51 Biggest Movers From Yesterday
April 06, 2022
Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are...
Via
Benzinga
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
April 05, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Adds Mental Health Testing Solutions Via AltheaDx Acquisition
April 05, 2022
Castle Biosciences Inc (NASDAQ: CSTL) has agreed to acquire AltheaDx Inc, a commercial-stage molecular diagnostics company,
Via
Benzinga
Castle Biosciences to Acquire AltheaDx
April 04, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
March 29, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
March 25, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences: Q4 Earnings Insights
February 28, 2022
Castle Biosciences (NASDAQ:CSTL) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
February 14, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 07, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases
February 18, 2022
Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
February 03, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
February 02, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
January 24, 2022
From
Castle Biosciences, Inc.
Via
Business Wire
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.